Clinical association analyses demonstrated that increased COMMD2 expression was correlated with higher histological grade, more advanced clinical stage, lymph node metastasis and the TP53 mutation status in LIHC patients. This evidence concerns the gene TP53 and metastatic malignant neoplasm in the lymph nodes.